CVKD Form 4: CEO Quang Pham reports pre-arranged stock sales

Rhea-AI Filing Summary

Cadrenal Therapeutics insider Form 4 summary: Director, CEO and Chairman Quang Pham reported pre-arranged sales of common stock under a Rule 10b5-1 trading plan. On 09/29/2025 he sold 419 shares at a weighted average price of $14.01, and on 10/01/2025 he sold 881 shares at a weighted average price of $14.01. Following these transactions Mr. Pham directly beneficially owned 202,633 shares. He also has indirect beneficial ownership of 200,000 shares through The PVBQ Living Trust, for which he is trustee and retains sole voting and dispositive power.

Positive

• Sales executed under a Rule 10b5-1 trading plan, indicating pre-arranged dispositions
• Filing discloses trust relationship and sole voting/disposition power, supporting transparency

Negative

• Insider sold common stock (total 1,300 shares reported), which could be viewed negatively by some investors

Insights

Securities Analyst

TL;DR: Insider sold small, pre-arranged blocks under a Rule 10b5-1 plan; ownership remains concentrated via direct and trust holdings.

The reported sales on 09/29/2025 (419 shares) and 10/01/2025 (881 shares) were executed under a Rule 10b5-1 arrangement at weighted average prices of $14.01. These transactions reduced direct holdings slightly to 202,633 shares while an indirect stake of 200,000 shares remains controlled through The PVBQ Living Trust. The use of a 10b5-1 plan indicates pre-planned dispositions rather than opportunistic sales; the absolute size of the sales is small relative to the remaining combined beneficial position of 402,633 shares.

Corporate Governance Expert

TL;DR: Disclosure is complete and includes trust detail; trustee retains sole voting and disposition power.

The filing discloses Mr. Pham's role as trustee of The PVBQ Living Trust and confirms sole voting and dispositive authority for the 200,000 trust shares. The filing includes explanatory notes about the 10b5-1 plan pricing ranges and offers to provide per-price sale details on request, which supports transparency and compliance with Section 16 reporting obligations. There is no indication of amendments or other compliance issues in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.,

822, A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/29/2025		S		419	D	$14.01(1)	203,514	D
Common Stock	10/01/2025		S		881	D	$14.01(2)	202,633	D
Common Stock								200,000	I	The PVBQ Living Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.02, inclusive, having a weighted average price as shown in column 4 of $14.01. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.05, inclusive, having a weighted average price as shown in column 4 of $14.01. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Matthew K. Szot, Attorney-in-fact	10/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for Cadrenal Therapeutics (CVKD)?

The Form 4 shows Quang Pham sold 419 shares on 09/29/2025 and 881 shares on 10/01/2025 under a Rule 10b5-1 plan at weighted average prices of $14.01.

How many CVKD shares does the reporting person beneficially own after these transactions?

Following the reported sales Mr. Pham directly beneficially owned 202,633 shares and had an indirect beneficial ownership of 200,000 shares through The PVBQ Living Trust.

What is the nature of the indirect ownership reported for CVKD?

Mr. Pham is the trustee of The PVBQ Living Trust and has sole voting and dispositive power over the 200,000 trust shares.

Were the sales part of an open-market plan or ad-hoc trades?

The filing states the sales were executed pursuant to a Rule 10b5-1 trading arrangement, indicating pre-arranged transactions.

Does the filing provide price details for each separate sale?

The Form 4 gives weighted average prices and price ranges and states the reporting person will provide details of the number of shares sold at each price on request.